Denali Gains 26.6% in a Year: How Should You Play the Stock?

Denali Therapeutics (DNLI) has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also outperformed the sector and the S&P 500 Index in this time frame.Denali is developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative and lysosomal storage diseases.  The upward price trajectory can be attributed to positive pipeline updates.DNL ...